Posted on September 21, 2020 by Sitemaster
Roche/Genentech’s investigational drug ipatasertib has demonstrated a small but statistically significant benefit in the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC) who had tumors exhibiting loss of the phosphatase and tensin (PTEN) homolog: a 2-month improvement in median radiographic progression-free survival (rPFS). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, ipatasertib, IPATential150, loss, metastatic, PTEN | 7 Comments »
Posted on September 10, 2020 by Sitemaster
At the end of this month, on Tuesday, September 29, at 8:00-9:30 p.m. Eastern time (to be precise), there will be a second webinar in the series on the role of active surveillance in the management of favorable-risk forms of localized prostate cancer, coordinated by our good friend Howard Wolinsky and others. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active, genetics, genomics, Helfand, surveillance, webinar | 2 Comments »
Posted on September 10, 2020 by Sitemaster
In 2013, Zumsteg et al. proposed a refinement in the NCCN “intermediate risk” classification into two subcategories, “favorable intermediate-risk (FIR)” and “unfavorable intermediate-risk (UIR).” … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: adjuvant, ADT, favorable, intermediate, radiation, risk, unfavorable | 3 Comments »
Posted on August 30, 2020 by Sitemaster
A researcher at the Medical University of South Carolina (MUSC) College of Nursing is conducting a study to better understand supportive care needs and quality of life among individuals with ADVANCED forms of prostate cancer and is seeking just a few more participants to complete this survey. Can you help (if you haven’t already)? … READ MORE …
Filed under: Uncategorized | Tagged: advanced, care, life, needs, quality, supportive, survey | 2 Comments »
Posted on August 29, 2020 by Sitemaster
The Prostate Active Surveillance Study (PASS), initially funded by the Canary Foundation, is a multi-center research study for men with low-risk disease who have chosen active surveillance (AS) to manage their prostate cancer. Active surveillance in PASS means closely monitoring men with prostate cancer and offering treatment if test results show the cancer is getting worse. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: active, AS, calculator, PASS, progression, risk, surveillance | Leave a comment »
Posted on August 26, 2020 by Sitemaster
Earlier today we reported on a recent publication based on data from the CaPSURE registry database, which stated that, among men enrolled in that database, men died sooner from their prostate cancer after they progressed to having metastatic disease over time (median survival, 2.4 years from onset of metastasis) than died from their prostate cancer if they were initially diagnosed with metastatic disease (median survival, 5.3 years). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, Diagnosis, metastatic, mortality, survival | 3 Comments »
Posted on August 26, 2020 by Sitemaster
Some readers are probably going to find this very hard to believe, but … according to a newly published study, men initially diagnosed with metastatic prostate cancer are actually less likely to die from their cancer than men who are initially diagnosed with non-metastatic disease but who progress to having metastatic disease over time. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management | Tagged: cancer-specific, Diagnosis, metastatic, mortality, survival | 4 Comments »
Posted on August 23, 2020 by Sitemaster
Two clinical trials have now confirmed the abscopal or bystander effect in prostate cancer. These effects occur when cancer cells that are not directly treated are nonetheless killed. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: abscopal, bystander, castration-resistant, effect, metastatic, Treatment | Leave a comment »
Posted on August 15, 2020 by Sitemaster
Earlier this year, at the annual Genitourinary Cancer symposium in San Francisco, we were first given information about the potential of three new tests for the diagnosis of prostate cancer: the so-called miR Sentinel tests from miR Scientific. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: Diagnosis, exome, miR, sentinel, test, urine | 9 Comments »
Posted on August 14, 2020 by Sitemaster
A company called Zenith Epigenetics has recently reported data from a Phase I/II clinical trial of a drug known as ZEN003604 or ZEN-3694 in the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC) who have progressed on treatment with either abiraterone + prednisone or enzlautamide (Xtandi). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer | Tagged: castration-resistant, enzautamide, mCRPC, metastatic, ZEN-3694 | 3 Comments »
Posted on August 12, 2020 by Sitemaster
An article published in Communications Biology has suggested that all prostate cancer patients should be routinely tested fro risk of infection with COVID-19. This appears to be a questionable piece of advice for the average prostate cancer patient. … READ MORE …
Filed under: Living with Prostate Cancer, Management | Tagged: COVID-19, risk, testing | Leave a comment »
Posted on August 12, 2020 by Sitemaster
We have recently learned that Movember conducted a major landscape analysis of unmet research needs in prostate cancer that started back in 2017 and ran through 2019 but just got published in 2020. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management | Tagged: analysis, landscape, Movember, need, priority, research | Leave a comment »
Posted on August 12, 2020 by Sitemaster
If you weren’t able to take part in the “live” presentation by Dr. Peter Carroll on “The past, present and future of active surveillance (AS)”, you can now view this either here on YouTube or here on the UroToday web site. This is the first in a series of four live video programs on AS-related topics. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active, surveillance | 2 Comments »
Posted on August 7, 2020 by Sitemaster
Eastham et al. have recently reported — in the Journal of Clinical Oncology — results from a randomized Phase III trial of the surgical treatment of men with high-risk forms of localized prostate cancer. … READ MORE …
Filed under: Management, Treatment | Tagged: "high risk", ADT, androgen, chemohormonal, chemotherapy, CHT, deprivation, localized, neoadjuvant, prostatectomy, radical, trial | 1 Comment »
Posted on August 7, 2020 by Sitemaster
A report this week in Urologic Oncology has confirmed the importance of PSA doubling times in understanding risk for prostate cancer progression among men with non-metastatic, castration-resistant prostate cancer (nmCRPC). … READ MORE …
Filed under: Uncategorized | Tagged: castration-resistant, doubling, mCRPC, metastasis, nmCRPC, non-metastatic, PSA, survival | 1 Comment »
